Furthermore, using four distinct ccRCC cell lines spiked in healthy donor’s blood, Maertens and colleagues demonstrated the superior recovery rates obtained by cell size-based enrichment (Parsortix, Angle PLC) over EpCAM-based collection of tumor cells and CD45-mediated depletion of leukocytes [67]. Here, EPCAM is linked to nonpapillary renal cell carcinoma.